| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients |
| 05 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 08 Sep 2026 |
8-K: Other Events
Corporate Update September 2026 BBOT Next-Generation RAS-Pathway Therapeutics |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Continued to advance monotherapy and combination cohorts for all clinical programs |
| 22 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs |
| 29 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 23 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman |
| 26 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 24, 2026, the board of directors (the “Board”) of BridgeBio Oncology Therapeutics, Inc. (the “Company”) increased the size of the Board to nine (9) directors and, upon the recommendation from the Nominating and Corporate Governa... |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. |
| 07 Jan 2026 |
8-K: Other Events
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations |
| 13 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +10 more
Unaudited Condensed Balance Sheets as of June 30, 2025 and December 31, 2024 |
| 06 Aug 2025 |
8-K: Regulation FD Disclosure
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics |
| 04 Aug 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On August 4, 2025, Helix Acquisition Corp. II (“Helix” or the “Company”) held an extraordinary general meeting (the “Extraordinary General Meeting”). At the Extraordinary General Meeting, an aggregate of 19,407,670 (82.55%) of the Compan... |
| 11 Jul 2025 |
8-K: Regulation FD Disclosure
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination |
| 03 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This BUSINESS COMBINATION AGREEMENT, dated as of __________, 2025 (this “Agreement”), is entered into by and among TheRas, Inc., a Delaware corporation (doing business as BridgeBio Oncology Therapeutics) (the “Company”), Helix Acquisitio... |
| 28 Feb 2025 |
8-K: Regulation FD Disclosure
Q1 2025 BridgeBio Oncology Therapeutics Confidential overview |
| 10 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and among Helix Acquisition Corp. II, a Cayman Islands exempted company (the “Co... |
| 20 Feb 2024 |
8-K: Other Events
We have audited the accompanying balance sheet of Helix Acquisition Corp. II (the “Company”) as of, February 13, 2024, and the related notes (collectively referred to as the “financial statement”). In our opinion, the financial statement... |
Loading...